$12.25 Million in Sales Expected for Alimera Sciences Inc (ALIM) This Quarter

Brokerages predict that Alimera Sciences Inc (NASDAQ:ALIM) will report $12.25 million in sales for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Alimera Sciences’ earnings, with estimates ranging from $12.00 million to $12.50 million. Alimera Sciences posted sales of $9.80 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 25%. The business is expected to announce its next earnings results on Thursday, May 2nd.

On average, analysts expect that Alimera Sciences will report full year sales of $55.18 million for the current year, with estimates ranging from $52.70 million to $57.65 million. For the next fiscal year, analysts anticipate that the business will report sales of $72.30 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that follow Alimera Sciences.

ALIM has been the topic of a number of research analyst reports. HC Wainwright set a $2.00 price objective on shares of Alimera Sciences and gave the stock a “buy” rating in a report on Wednesday, February 20th. Zacks Investment Research downgraded shares of Alimera Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, January 8th. Finally, ValuEngine raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $2.44.

Hedge funds and other institutional investors have recently made changes to their positions in the business. B. Riley Wealth Management Inc. purchased a new stake in shares of Alimera Sciences in the third quarter valued at about $81,000. Royce & Associates LP purchased a new stake in shares of Alimera Sciences in the third quarter valued at about $195,000. Knott David M lifted its holdings in shares of Alimera Sciences by 20.1% in the fourth quarter. Knott David M now owns 387,901 shares of the biopharmaceutical company’s stock valued at $279,000 after purchasing an additional 65,001 shares in the last quarter. B. Riley Financial Inc. purchased a new stake in shares of Alimera Sciences in the third quarter valued at about $447,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of Alimera Sciences by 27.7% in the third quarter. Renaissance Technologies LLC now owns 732,790 shares of the biopharmaceutical company’s stock valued at $718,000 after purchasing an additional 158,790 shares in the last quarter. 50.32% of the stock is currently owned by institutional investors.

ALIM stock traded down $0.04 during trading on Friday, reaching $0.92. 84,064 shares of the company were exchanged, compared to its average volume of 100,849. The company has a market cap of $66.55 million, a P/E ratio of -3.17 and a beta of 2.22. Alimera Sciences has a 52-week low of $0.72 and a 52-week high of $1.21.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness.

Further Reading: What are economic reports?

Get a free copy of the Zacks research report on Alimera Sciences (ALIM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit